brand logo

Am Fam Physician. 2022;105(6):591-592

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial relationships.

Clinical Question

Are selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) safe and effective for the treatment of premature ejaculation in adult men?

Evidence-Based Answer

SSRIs and SNRIs increase the ejaculatory latency time (mean difference [MD] = 3.09 minutes; 95% CI, 1.94 to 4.25 minutes) and improve the satisfaction of the experience (relative risk [RR] = 1.63; 95% CI, 1.42 to 1.87) compared with placebo. However, adverse effects cause a substantial number of men to stop treatment (RR = 3.80; 95% CI, 2.61 to 5.51).1 (Strength of Recommendation: B, inconsistent or limited-quality patient-oriented evidence.)

Practice Pointers

According to the International Society for Sexual Medicine, premature ejaculation is a sexual dysfunction characterized by penile ejaculation that always or nearly always occurs before or within one minute of sexual penetration.2 It is either present from the patient's first sexual encounter (lifelong premature ejaculation) or a bothersome decrease in ejaculatory latency (secondary or acquired), often to three minutes or less. Causes of acquired premature ejaculation include sexual performance anxiety, psychological and relationship problems, erectile dysfunction, and use of or withdrawal from medications or recreational drugs. Rarely, hyperthyroidism or prostatitis can contribute to premature ejaculation. In lifelong and acquired premature ejaculation, there is an inability to delay ejaculation during all or nearly all instances of sexual penetration, leading to personal distress or avoidance of sexual intimacy.1,3,4 

Premature ejaculation is estimated to occur in 4% to 39% of men in the general population.5 Premature ejaculation can be treated using a multimodal approach, including behavioral therapy, topical agents, and oral medications.5 The authors of this Cochrane review sought to determine whether SSRIs or SNRIs can improve symptoms of premature ejaculation in adult men. 

This Cochrane review included 31 randomized controlled trials in which 8,254 participants received SSRIs (n = 4,990), another drug, or placebo.1 The studies included only men 18 years and older with lifelong premature ejaculation; 4,193 men received dapoxetine, an SSRI that is marketed to promote ejaculatory delay and is not available in the United States. The studies were conducted across 14 countries, including three in the United States and Canada. A range of other SSRIs and SNRIs were used at different dosages in the studies, including fluoxetine (Prozac), duloxetine (Cymbalta), citalopram (Celexa), sertraline (Zoloft), paroxetine (Paxil), escitalopram (Lexapro), and fluvoxamine. In some studies, the SSRI was prescribed as a daily medication for premature ejaculation. In other studies, the medication was meant to be used on demand just before sexual activity. Dapoxetine, paroxetine, and citalopram were in the on-demand arms. 

Perception of change with treatment was evaluated using the Clinical Global Impression of Change questionnaire, a validated clinician-completed instrument to assess response to treatment. Participants who received an SSRI or SNRI were two times more likely to report change with treatment compared with those who received placebo (number needed to treat [NNT] = 5; 95% CI, 4 to 7). Participants who received an SSRI or SNRI had increased intravaginal ejaculatory latency time compared with those who received placebo (MD = 3.09 minutes; 95% CI, 1.94 to 4.25 minutes). Satisfaction with intercourse and perceived control over ejaculation with dapoxetine were measured using a validated instrument called the Premature Ejaculation Profile questionnaire. Participants treated with an SSRI or SNRI were more likely to experience satisfaction (RR = 1.63; 95% CI, 1.42 to 1.87) and to perceive control over ejaculation (RR = 2.29; 95% CI, 1.72 to 3.05) compared with those who were given placebo. 

When dapoxetine was used daily or on demand just before sexual activity, the effectiveness of 30-mg and 60-mg dosing for premature ejaculation was similar for all of the above outcomes. However, participants who received 60 mg of dapoxetine daily or on demand were much more likely to withdraw from the studies because of adverse effects compared with those who received 30 mg of dapoxetine. A substantial number of participants withdrew from the studies because of adverse effects with SSRI use (number needed to harm [NNH] = 33; 95% CI, 20 to 59). The adverse effects experienced by these participants were not described in this review. 

Already a member/subscriber?  Log In


From $145
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

These are summaries of reviews from the Cochrane Library.

This series is coordinated by Corey D. Fogleman, MD, assistant medical editor.

A collection of Cochrane for Clinicians published in AFP is available at

Continue Reading

More in AFP

More in Pubmed

Copyright © 2022 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.